AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16534240 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 microg intravenously administered CRH
Number of subjects: 16
Study 16534240 — intervention group
Group type: COMPARATOR
Intervention: 12 mg naloxone
Number of subjects: 16
Study 16534240 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 12011663 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (50 mg three times a day)
Number of subjects: 128
Study 12011663 — intervention group
Group type: COMPARATOR
Intervention: Lisinopril (10-20 mg once daily)
Number of subjects: 128
Study 12011663 — intervention group
Group type: COMPARATOR
Intervention: Valsartan (80-160 mg once daily)
Number of subjects: 128
Study 10850318 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg/m2 amifostine intravenously prior to HD-RIT
Number of subjects: 50
Study 10850318 — intervention group
Group type: COMPARATOR
Intervention: Physiological saline solution (control)
Number of subjects: 50
Study 10850318 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg/kg amifostine prior to HD-RIT in rabbits
Number of subjects: 50
Study 10850318 — intervention group
Group type: COMPARATOR
Intervention: Control rabbits (no amifostine)
Number of subjects: 50
Study 8709384 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E1 with sodium bicarbonate
Number of subjects: 10
Study 8709384 — intervention group
Group type: COMPARATOR
Intervention: Prostaglandin E1 without sodium bicarbonate
Number of subjects: 10
Study 1936073 — intervention group
Group type: EXPERIMENTAL
Intervention: Rokitamycin 200 mg
Number of subjects: 12
Study 1936073 — intervention group
Group type: EXPERIMENTAL
Intervention: Rokitamycin 300 mg
Number of subjects: 12
Study 1936073 — intervention group
Group type: EXPERIMENTAL
Intervention: Rokitamycin 400 mg
Number of subjects: 12
Study 1936073 — intervention group
Group type: EXPERIMENTAL
Intervention: Rokitamycin 600 mg
Number of subjects: 12
Study 6791673 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside
Number of subjects: 22
Study 6791673 — intervention group
Group type: EXPERIMENTAL
Intervention: Trinitroglycerine
Number of subjects: 22
Study 29525393 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinacalcet
Number of subjects: 3851
Study 29525393 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3851
Study 29525393 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention (active vitamin D sterol dose increase)
Number of subjects: 3851
Study 27508314 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive Reminder System (health belief education, calendar handbook, weekly automated SMS, four telephone follow-ups)
Number of subjects: 0
Study 27508314 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 24886036 — intervention group
Group type: EXPERIMENTAL
Intervention: Lecithinized superoxide dismutase (40 or 80 mg)
Number of subjects: 0
Study 24886036 — intervention group
Group type: EXPERIMENTAL
Intervention: Lecithinized superoxide dismutase (80 mg)
Number of subjects: 0
Study 24886036 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 22429451 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-stretch bandaging (SSB)
Number of subjects: 321
Study 22429451 — intervention group
Group type: EXPERIMENTAL
Intervention: Four-layer bandaging (4LB)
Number of subjects: 321
Study 22429451 — intervention group
Group type: COMPARATOR
Intervention: Usual care (moist wound healing dressing without compression)
Number of subjects: 321
Study 22429451 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression-treated groups (SSB and 4LB)
Number of subjects: 321
Study 20563466 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine PCA alone (Group A)
Number of subjects: 100
Study 20563466 — intervention group
Group type: COMPARATOR
Intervention: Morphine PCA plus continuous infusion (Group B)
Number of subjects: 100
Study 18520951 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosinopril/hydrochlorothiazide combination (10/12.5 mg titrated up to 20/12.5 mg)
Number of subjects: 28
Study 18520951 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine (5 mg titrated up to 10 mg)
Number of subjects: 28
Study 18520951 — intervention group
Group type: COMPARATOR
Intervention: Indapamide (2.5 mg)
Number of subjects: 28
Study 15939732 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous aminophylline 0.5 mg/kg/hour after an appropriate loading dose
Number of subjects: 80
Study 15939732 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% saline)
Number of subjects: 80
Study 15939732 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous aminophylline
Number of subjects: 80
Study 12463729 — intervention group
Group type: EXPERIMENTAL
Intervention: Galantamine and risperidone administered together
Number of subjects: 16
Study 12463729 — intervention group
Group type: COMPARATOR
Intervention: Galantamine and risperidone administered alone
Number of subjects: 16
Study 10618647 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenretinide (synthetic retinoid)
Number of subjects: 99
Study 10618647 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional cytology
Number of subjects: 99
Study 10618647 — intervention group
Group type: EXPERIMENTAL
Intervention: DNA flow cytometry
Number of subjects: 99
Study 7851589 — intervention group
Group type: EXPERIMENTAL
Intervention: 16 mg oral 6-alpha-methylprednisolone for four evenings starting the evening of retrieval or the evening before thawing cryopreserved embryos, plus 250 mg oral tetracycline four times per day for 4 days.
Number of subjects: 267
Study 7851589 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered in an identical fashion, plus 250 mg oral tetracycline four times per day for 4 days.
Number of subjects: 267
Study 1658546 — intervention group
Group type: EXPERIMENTAL
Intervention: hCRH plus 0.3 U IV AVP
Number of subjects: 16
Study 1658546 — intervention group
Group type: COMPARATOR
Intervention: hCRH alone
Number of subjects: 16
Study 1658546 — intervention group
Group type: EXPERIMENTAL
Intervention: hCRH plus 3.0 U IM AVP
Number of subjects: 16
Study 1658546 — intervention group
Group type: EXPERIMENTAL
Intervention: hCRH plus 5.0 U IM AVP
Number of subjects: 16
Study 6127319 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobramycin (1 mg/kg body weight)
Number of subjects: 30
Study 6127319 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobramycin (1 mg/kg body weight) + Cefotaxime (2 g)
Number of subjects: 30
Study 6127319 — intervention group
Group type: COMPARATOR
Intervention: Cefotaxime (2 g)
Number of subjects: 30
Study 31169417 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic interval training (AIT) for 12 weeks, 36 sessions total.
Number of subjects: 30
Study 31169417 — intervention group
Group type: COMPARATOR
Intervention: Sedentary control group (no specific intervention mentioned).
Number of subjects: 30
Study 28623433 — intervention group
Group type: EXPERIMENTAL
Intervention: Honey
Number of subjects: 56
Study 28623433 — intervention group
Group type: COMPARATOR
Intervention: Mefenamic acid
Number of subjects: 56
Study 25376729 — intervention group
Group type: EXPERIMENTAL
Intervention: SIE (sprint interval exercise; 4 all-out 30-s sprints)
Number of subjects: 10
Study 25376729 — intervention group
Group type: EXPERIMENTAL
Intervention: CELOW (continuous exercise at 46% VO2peak)
Number of subjects: 10
Study 25376729 — intervention group
Group type: EXPERIMENTAL
Intervention: CEHIGH (continuous exercise at 77% VO2peak)
Number of subjects: 10
Study 25376729 — intervention group
Group type: COMPARATOR
Intervention: CON (non-exercise trial)
Number of subjects: 10
Study 23351827 — intervention group
Group type: EXPERIMENTAL
Intervention: LABR‐312 (low-dose)
Number of subjects: 225
Study 23351827 — intervention group
Group type: EXPERIMENTAL
Intervention: LABR‐312 (high-dose)
Number of subjects: 225
Study 23351827 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 225
Study 23351827 — intervention group
Group type: EXPERIMENTAL
Intervention: LABR‐312 (inflammatory patient group)
Number of subjects: 225
Study 21081771 — intervention group
Group type: EXPERIMENTAL
Intervention: Anesthesiologists ordering tests
Number of subjects: 1000
Study 21081771 — intervention group
Group type: COMPARATOR
Intervention: Anesthesiologists
Number of subjects: 1000
Study 19336860 — intervention group
Group type: EXPERIMENTAL
Intervention: Oil pulling with sesame oil
Number of subjects: 20
Study 19336860 — intervention group
Group type: COMPARATOR
Intervention: Chlorhexidine mouthwash
Number of subjects: 20
Study 16629914 — intervention group
Group type: EXPERIMENTAL
Intervention: Self‐Efficacy Goal Achievement nursing intervention
Number of subjects: 8
Study 15152381 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive strategies including staff education, increasing safety during nursing interventions, research for risk indicators of self‐extubation, patient's comfort and sedation protocols, alternative methods to physical and pharmacological restraints.
Number of subjects: 0
Study 11703951 — intervention group
Group type: EXPERIMENTAL
Intervention: Eptifibatide 135 microg/kg bolus followed by 0.75 microg/kg/min infusion
Number of subjects: 127
Study 11703951 — intervention group
Group type: EXPERIMENTAL
Intervention: Eptifibatide 180 microg/kg bolus followed by 2.0 microg/kg/min infusion
Number of subjects: 127
Study 11703951 — intervention group
Group type: EXPERIMENTAL
Intervention: Eptifibatide 250 microg/kg bolus followed by 3.0 microg/kg/min infusion
Number of subjects: 127
Study 11703951 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 127
Study 9141536 — intervention group
Group type: COMPARATOR
Intervention: [Nle27]GHRH-(1-29)-NH2 at a dose of 10 microg/kg, administered nightly for 16 weeks after 4 weeks of placebo.
Number of subjects: 19
Study 9141536 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline) self-injected s.c. nightly for 4 weeks.
Number of subjects: 19
Study 9141536 — intervention group
Group type: EXPERIMENTAL
Intervention: [Nle27]GHRH-(1-29)-NH2
Number of subjects: 19
Study 7867114 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine hydrochloride, 0.03 mg.kg‐1 iv
Number of subjects: 45
Study 7867114 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil hydrochloride, 0.1 mg.kg‐1 iv
Number of subjects: 45
Study 7867114 — intervention group
Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 45
Study 2765348 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine 15 mg plus clonidine 1 ml (150 micrograms)
Number of subjects: 30
Study 2765348 — intervention group
Group type: COMPARATOR
Intervention: 0.5% isobaric bupivacaine 15 mg plus isotonic saline 1 ml
Number of subjects: 30
Study 49560 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-administered nitrous oxide 50%/oxygen 50% ('Entonox' analgesic apparatus)
Number of subjects: 81
Study 49560 — intervention group
Group type: COMPARATOR
Intervention: Air (control group)
Number of subjects: 81
Study 31393430 — intervention group
Group type: EXPERIMENTAL
Intervention: Section of SLIL+LRL
Number of subjects: 30
Study 31393430 — intervention group
Group type: EXPERIMENTAL
Intervention: Section of SLIL+DIC
Number of subjects: 30
Study 31393430 — intervention group
Group type: EXPERIMENTAL
Intervention: Section of SLIL+STT
Number of subjects: 30
Study 31393430 — intervention group
Group type: EXPERIMENTAL
Intervention: Section of SLIL+DIC+DIC
Number of subjects: 30
Study 31393430 — intervention group
Group type: EXPERIMENTAL
Intervention: Division of SLIL
Number of subjects: 30
Study 25578926 — intervention group
Group type: EXPERIMENTAL
Intervention: ¡Cocinar Para Su Salud! (Intervention group, n=34)
Number of subjects: 70
Study 25578926 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=36)
Number of subjects: 70
Study 23222003 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary nitroglycerin (250-μg)
Number of subjects: 60
Study 23222003 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary diltiazem (5-mg)
Number of subjects: 60
Study 21624218 — intervention group
Group type: EXPERIMENTAL
Intervention: Early intervention group (coronary angiography taken within 24 hours after grouping)
Number of subjects: 815
Study 21624218 — intervention group
Group type: COMPARATOR
Intervention: Delayed intervention group (coronary angiography taken after 36 hours after grouping)
Number of subjects: 815
Study 21624218 — intervention group
Group type: EXPERIMENTAL
Intervention: Early intervention group
Number of subjects: 815
Study 21624218 — intervention group
Group type: COMPARATOR
Intervention: Delayed intervention group
Number of subjects: 815
Study 19064513 — intervention group
Group type: COMPARATOR
Intervention: Vitamin D(3) 0 microg/d
Number of subjects: 238
Study 19064513 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D(3) 5 microg/d
Number of subjects: 238
Study 19064513 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D(3) 10 microg/d
Number of subjects: 238
Study 19064513 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D(3) 15 microg/d
Number of subjects: 238
Study 16681964 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical resection (SR)
Number of subjects: 105
Study 16681964 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous thermal ablation (PTA)
Number of subjects: 105
Study 15115098 — intervention group
Group type: EXPERIMENTAL
Intervention: High-lactose Bifidobacterium bifidum-containing formula
Number of subjects: 100
Study 15115098 — intervention group
Group type: COMPARATOR
Intervention: Control group (no high-lactose probiotic)
Number of subjects: 100
Study 11138763 — intervention group
Group type: EXPERIMENTAL
Intervention: Listeners making specific responses (e.g., wincing, exclaiming)
Number of subjects: 63
Study 11138763 — intervention group
Group type: EXPERIMENTAL
Intervention: Listeners making generic responses (e.g., nodding, vocalizations)
Number of subjects: 63
Study 8791866 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine (CQ)
Number of subjects: 208
Study 1645076 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary catheterisation
Number of subjects: 78
Study 1645076 — intervention group
Group type: COMPARATOR
Intervention: Incontinence pads
Number of subjects: 78
Study 6360259 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone
Number of subjects: 28
Study 6360259 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline
Number of subjects: 28
Study 6360259 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine
Number of subjects: 28
Study 30408848 — intervention group
Group type: EXPERIMENTAL
Intervention: Concizumab
Number of subjects: 0
Study 30366975 — intervention group
Group type: EXPERIMENTAL
Intervention: IV alteplase
Number of subjects: 2916
Study 30366975 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 2916
Study 26881789 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive Health Enhancement Support System (CHESS)
Number of subjects: 90
Study 24159007 — intervention group
Group type: EXPERIMENTAL
Intervention: Focused nutrition educational intervention plus $6 in coupons redeemable at farmers markets
Number of subjects: 78
Study 24159007 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 78
Study 22270285 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-incision mini-sling
Number of subjects: 263
Study 22270285 — intervention group
Group type: COMPARATOR
Intervention: Tension-free vaginal tape (TVT)
Number of subjects: 263
Study 19803399 — intervention group
Group type: EXPERIMENTAL
Intervention: IV rt‐PA therapy at a dose of 0.9 mg/kg
Number of subjects: 0
Study 19803399 — intervention group
Group type: EXPERIMENTAL
Intervention: IV rt‐PA therapy at a dose of 0.6 mg/kg
Number of subjects: 0
Study 19803399 — intervention group
Group type: COMPARATOR
Intervention: IV rt‐PA administered 3‐4.5 hours after symptom onset
Number of subjects: 0
Study 19803399 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI-based thrombolysis
Number of subjects: 0
Study 19803399 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of reperfusion therapies (IV rt‐PA and sonothrombolysis, neuroprotective agents, or antiplatelet agents)
Number of subjects: 0
Study 19803399 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher dose of alteplase, combined IV/IA thrombolysis, or mechanical thrombectomy
Number of subjects: 0
Study 17488248 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular octreotide 20 mg (group A) q 4 wk for 3 months
Number of subjects: 18
Study 17488248 — intervention group
Group type: COMPARATOR
Intervention: Placebo (group B)
Number of subjects: 18
Study 14961057 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomipramine 25 mg as needed
Number of subjects: 23
Study 14961057 — intervention group
Group type: COMPARATOR
Intervention: Clomipramine 20 or 30 mg daily
Number of subjects: 23
Study 12516788 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 grams of superactivated charcoal (SAC) administered orally in a slurry 3 hours after acetaminophen dose
Number of subjects: 48
Study 12516788 — intervention group
Group type: COMPARATOR
Intervention: No charcoal (control group)
Number of subjects: 48
Study 9862941 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole and antibiotics (20 mg omeprazole orally twice daily, 500 mg amoxicillin three times daily, 400 mg metronidazole three times daily for 2 weeks)
Number of subjects: 318
Study 9862941 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole and antibiotics
Number of subjects: 318
Study 9862941 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole alone
Number of subjects: 318
Study 9818646 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-depleting humanized monoclonal antibody to CD4 (ORTHOCLONE OKTcdr4a) at a dosage of +/-450 mg per week for 2 treatment cycles, followed by a crossover to placebo for the third cycle.
Number of subjects: 0
Study 9818646 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2695726 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 x 1 g claforan given during a period of 24 h (regimen I)
Number of subjects: 65
Study 2695726 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 x 1 g claforan given at the time of incision (regimen II)
Number of subjects: 65
Study 2695726 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of cefapirin + gentamicin given in divided doses for 5 days (regimen III)
Number of subjects: 65
Study 719463 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous load of 11 of Hartmann's solution
Number of subjects: 104
Study 719463 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intravenous load)
Number of subjects: 104
Study 31212508 — intervention group
Group type: EXPERIMENTAL
Intervention: CycleSampler method for generating surrogate networks with edge weights constrained to intervals and vertex strengths preserved exactly.
Number of subjects: 0
Study 31212508 — intervention group
Group type: EXPERIMENTAL
Intervention: CycleSampler method for generating surrogate networks with both edge and vertex strengths constrained to intervals.
Number of subjects: 0
Study 28533045 — intervention group
Group type: EXPERIMENTAL
Intervention: Animal-assisted therapy sessions
Number of subjects: 0
Study 25593483 — intervention group
Group type: EXPERIMENTAL
Intervention: RetroView™ colonoscope in retroflexed withdrawal
Number of subjects: 5
Study 25593483 — intervention group
Group type: EXPERIMENTAL
Intervention: RetroView™ colonoscope in combination withdrawal (standard + retroflexed)
Number of subjects: 5
Study 25593483 — intervention group
Group type: EXPERIMENTAL
Intervention: RetroView™ colonoscope in retroflexed withdrawal alone
Number of subjects: 5
Study 25593483 — intervention group
Group type: COMPARATOR
Intervention: Conventional colonoscope in standard withdrawal
Number of subjects: 5
Study 23974970 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser‐assisted posterior cordotomy (Group A)
Number of subjects: 20
Study 23974970 — intervention group
Group type: COMPARATOR
Intervention: Diathermy‐assisted posterior cordotomy (Group B)
Number of subjects: 20
Study 21689442 — intervention group
Group type: EXPERIMENTAL
Intervention: Edinburgh Postnatal Depression Scale (EPDS)
Number of subjects: 811
Study 19785777 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual teaching (lecture followed by group tutorial)
Number of subjects: 129
Study 19785777 — intervention group
Group type: COMPARATOR
Intervention: Problem Based Learning (PBL)
Number of subjects: 129
Study 16910765 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetyl-cysteine (NAC) treatment
Number of subjects: 0
Study 16910765 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro exposure of RBC to ROS/RNS
Number of subjects: 0
Study 15242836 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxic apnea
Number of subjects: 21
Study 15242836 — intervention group
Group type: COMPARATOR
Intervention: Hypercapnic hypoxia
Number of subjects: 21
Study 15242836 — intervention group
Group type: COMPARATOR
Intervention: Isocapnic hypoxia
Number of subjects: 21
Study 11388971 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinician-accompanied self-exposure
Number of subjects: 68
Study 11388971 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-exposure
Number of subjects: 68
Study 11388971 — intervention group
Group type: COMPARATOR
Intervention: Self-relaxation
Number of subjects: 68
Study 11388971 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-exposure homework compliance
Number of subjects: 68
Study 11388971 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment need
Number of subjects: 68
Study 9240144 — intervention group
Group type: EXPERIMENTAL
Intervention: Urgent carotid surgery
Number of subjects: 16
Study 9240144 — intervention group
Group type: COMPARATOR
Intervention: Best medical care
Number of subjects: 16
Study 7685687 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac alone
Number of subjects: 0
Study 7685687 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol alone
Number of subjects: 0
Study 7685687 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac/misoprostol combination dosage form
Number of subjects: 0
Study 7685687 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac (single and multiple doses) in elderly volunteers
Number of subjects: 0
Study 3718599 — intervention group
Group type: EXPERIMENTAL
Intervention: Acemetacin (90 mg, single administration)
Number of subjects: 14
Study 3718599 — intervention group
Group type: EXPERIMENTAL
Intervention: Acemetacin (2 retard capsules/d for 8 d, multiple administration)
Number of subjects: 14
Study 29449080 — intervention group
Group type: EXPERIMENTAL
Intervention: MAX-LEG
Number of subjects: 13
Study 29449080 — intervention group
Group type: EXPERIMENTAL
Intervention: MAX-ARM
Number of subjects: 13